Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
In the STEP 2 trial, patients with type 2 diabetes lost an average of 9.6% of body weight while also improving their HbA1c levels
Group 3 ( n = 8) 16-h fasting mice
About Wegovy HD (semaglutide) injection 7.2 mg The FDA approval of Wegovy HD is based on the results of the STEP UP program, which included the phase 3 STEP UP clinical trial, which was a 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of once-weekly semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention
These results suggest that GLP1R agonists in combination with a calcitonin receptor agonist, is able to show even larger decreases in body weight than typical GLP1R agonists, within a shorter time and with a more favourable side effect profile
What is the danger of semaglutide
